nodes	percent_of_prediction	percent_of_DWPC	metapath
Amphetamine—SLC6A4—conduct disorder	0.848	1	CbGaD
Amphetamine—MAOB—Biogenic amines are oxidatively deaminated to aldehydes by MAOA and MAOB—MAOA—conduct disorder	0.0183	0.135	CbGpPWpGaD
Amphetamine—MAOB—Amine Oxidase reactions—MAOA—conduct disorder	0.0105	0.0774	CbGpPWpGaD
Amphetamine—SLC6A3—Clearance of dopamine—COMT—conduct disorder	0.00777	0.0572	CbGpPWpGaD
Amphetamine—SLC6A3—Clearance of dopamine—MAOA—conduct disorder	0.00772	0.0568	CbGpPWpGaD
Amphetamine—DRD2—Dopamine receptors—DRD4—conduct disorder	0.00515	0.0379	CbGpPWpGaD
Amphetamine—CARTPT—Circadian rythm related genes—SLC6A4—conduct disorder	0.00463	0.0341	CbGpPWpGaD
Amphetamine—CARTPT—Circadian rythm related genes—DRD4—conduct disorder	0.00436	0.0321	CbGpPWpGaD
Amphetamine—MAOB—Dopamine metabolism—COMT—conduct disorder	0.00412	0.0304	CbGpPWpGaD
Amphetamine—TAAR1—Amine ligand-binding receptors—DRD4—conduct disorder	0.0041	0.0302	CbGpPWpGaD
Amphetamine—MAOB—Dopamine metabolism—MAOA—conduct disorder	0.0041	0.0301	CbGpPWpGaD
Amphetamine—SLC6A4—Serotonin Transporter Activity—MAOA—conduct disorder	0.00358	0.0264	CbGpPWpGaD
Amphetamine—SLC6A3—Neurotransmitter Clearance In The Synaptic Cleft—COMT—conduct disorder	0.00355	0.0261	CbGpPWpGaD
Amphetamine—SLC6A3—Neurotransmitter Clearance In The Synaptic Cleft—MAOA—conduct disorder	0.00352	0.0259	CbGpPWpGaD
Amphetamine—SLC18A2—Nicotine Activity on Dopaminergic Neurons—DRD4—conduct disorder	0.00341	0.0251	CbGpPWpGaD
Amphetamine—SLC18A2—Norepinephrine Neurotransmitter Release Cycle—MAOA—conduct disorder	0.00309	0.0227	CbGpPWpGaD
Amphetamine—TAAR1—G alpha (s) signalling events—CGA—conduct disorder	0.00302	0.0222	CbGpPWpGaD
Amphetamine—SLC6A2—autonomic nervous system—conduct disorder	0.00291	0.395	CbGeAlD
Amphetamine—TAAR1—Amine ligand-binding receptors—HTR2A—conduct disorder	0.00267	0.0197	CbGpPWpGaD
Amphetamine—SLC18A2—Synaptic Vesicle Pathway—SLC6A4—conduct disorder	0.00178	0.0131	CbGpPWpGaD
Amphetamine—SLC6A2—Monoamine Transport—SLC6A4—conduct disorder	0.00174	0.0128	CbGpPWpGaD
Amphetamine—DRD2—Nicotine Activity on Dopaminergic Neurons—DRD4—conduct disorder	0.00163	0.012	CbGpPWpGaD
Amphetamine—Pargyline—MAOA—conduct disorder	0.00163	0.18	CrCbGaD
Amphetamine—SLC18A2—Neurotransmitter Release Cycle—MAOA—conduct disorder	0.00157	0.0115	CbGpPWpGaD
Amphetamine—SLC6A3—Monoamine Transport—SLC6A4—conduct disorder	0.00154	0.0114	CbGpPWpGaD
Amphetamine—SLC22A3—Synaptic Vesicle Pathway—SLC6A4—conduct disorder	0.00154	0.0114	CbGpPWpGaD
Amphetamine—CARTPT—Circadian rythm related genes—EP300—conduct disorder	0.00151	0.0111	CbGpPWpGaD
Amphetamine—TAAR1—Class A/1 (Rhodopsin-like receptors)—CGA—conduct disorder	0.00144	0.0106	CbGpPWpGaD
Amphetamine—CARTPT—brain—conduct disorder	0.00136	0.184	CbGeAlD
Amphetamine—DRD2—Hypothetical Network for Drug Addiction—DRD4—conduct disorder	0.00117	0.00858	CbGpPWpGaD
Amphetamine—DRD2—Monoamine GPCRs—DRD4—conduct disorder	0.00114	0.00837	CbGpPWpGaD
Amphetamine—TAAR1—GPCR ligand binding—CGA—conduct disorder	0.0011	0.00807	CbGpPWpGaD
Amphetamine—Tranylcypromine—MAOA—conduct disorder	0.00105	0.116	CrCbGaD
Amphetamine—Phenylpropanolamine—MAOA—conduct disorder	0.000987	0.109	CrCbGaD
Amphetamine—MAOB—Phase 1 - Functionalization of compounds—MAOA—conduct disorder	0.000977	0.00719	CbGpPWpGaD
Amphetamine—DRD2—Amine ligand-binding receptors—DRD4—conduct disorder	0.000956	0.00704	CbGpPWpGaD
Amphetamine—SLC18A2—Transmission across Chemical Synapses—GABRA2—conduct disorder	0.000941	0.00693	CbGpPWpGaD
Amphetamine—Phentermine—MAOA—conduct disorder	0.00088	0.0973	CrCbGaD
Amphetamine—Pseudoephedrine—MAOA—conduct disorder	0.000834	0.0922	CrCbGaD
Amphetamine—Selegiline—MAOA—conduct disorder	0.000814	0.09	CrCbGaD
Amphetamine—TAAR1—Class A/1 (Rhodopsin-like receptors)—DRD4—conduct disorder	0.000806	0.00593	CbGpPWpGaD
Amphetamine—DRD2—Monoamine GPCRs—HTR2A—conduct disorder	0.000742	0.00546	CbGpPWpGaD
Amphetamine—SLC18A2—Neuronal System—GABRA2—conduct disorder	0.000721	0.00531	CbGpPWpGaD
Amphetamine—Phenelzine—MAOA—conduct disorder	0.000717	0.0793	CrCbGaD
Amphetamine—Methamphetamine—MAOA—conduct disorder	0.000627	0.0693	CrCbGaD
Amphetamine—DRD2—Amine ligand-binding receptors—HTR2A—conduct disorder	0.000624	0.00459	CbGpPWpGaD
Amphetamine—TAAR1—GPCR downstream signaling—CGA—conduct disorder	0.00062	0.00456	CbGpPWpGaD
Amphetamine—TAAR1—GPCR ligand binding—DRD4—conduct disorder	0.000614	0.00452	CbGpPWpGaD
Amphetamine—CYP2D6—Melatonin metabolism and effects—MAOA—conduct disorder	0.000589	0.00433	CbGpPWpGaD
Amphetamine—Phentermine—SLC6A4—conduct disorder	0.000567	0.0627	CrCbGaD
Amphetamine—TAAR1—Signaling by GPCR—CGA—conduct disorder	0.000563	0.00414	CbGpPWpGaD
Amphetamine—SLC6A3—Transmission across Chemical Synapses—GABRA2—conduct disorder	0.000561	0.00413	CbGpPWpGaD
Amphetamine—Pseudoephedrine—SLC6A4—conduct disorder	0.000538	0.0594	CrCbGaD
Amphetamine—TAAR1—Class A/1 (Rhodopsin-like receptors)—HTR2A—conduct disorder	0.000526	0.00387	CbGpPWpGaD
Amphetamine—MAOB—Biological oxidations—COMT—conduct disorder	0.000523	0.00385	CbGpPWpGaD
Amphetamine—MAOB—Biological oxidations—MAOA—conduct disorder	0.000519	0.00382	CbGpPWpGaD
Amphetamine—SLC6A2—NRF2 pathway—SLC6A4—conduct disorder	0.000517	0.00381	CbGpPWpGaD
Amphetamine—CYP2A6—Phase 1 - Functionalization of compounds—MAOA—conduct disorder	0.000476	0.0035	CbGpPWpGaD
Amphetamine—SLC18A2—brain—conduct disorder	0.000461	0.0626	CbGeAlD
Amphetamine—SLC6A3—NRF2 pathway—SLC6A4—conduct disorder	0.000458	0.00337	CbGpPWpGaD
Amphetamine—SLC18A2—Transmission across Chemical Synapses—COMT—conduct disorder	0.000453	0.00334	CbGpPWpGaD
Amphetamine—SLC18A2—Transmission across Chemical Synapses—MAOA—conduct disorder	0.00045	0.00331	CbGpPWpGaD
Amphetamine—SLC6A4—Circadian rythm related genes—DRD4—conduct disorder	0.000438	0.00322	CbGpPWpGaD
Amphetamine—SLC6A3—Neuronal System—GABRA2—conduct disorder	0.00043	0.00316	CbGpPWpGaD
Amphetamine—SLC6A4—SIDS Susceptibility Pathways—MAOA—conduct disorder	0.000429	0.00316	CbGpPWpGaD
Amphetamine—CYP2A6—brain—conduct disorder	0.000411	0.0559	CbGeAlD
Amphetamine—Methamphetamine—SLC6A4—conduct disorder	0.000404	0.0447	CrCbGaD
Amphetamine—TAAR1—GPCR ligand binding—HTR2A—conduct disorder	0.000401	0.00295	CbGpPWpGaD
Amphetamine—SLC18A2—Transmembrane transport of small molecules—GABRA2—conduct disorder	0.000388	0.00285	CbGpPWpGaD
Amphetamine—CYP2A6—NRF2 pathway—SLC6A4—conduct disorder	0.000383	0.00282	CbGpPWpGaD
Amphetamine—SLC6A4—SIDS Susceptibility Pathways—HTR2A—conduct disorder	0.00035	0.00258	CbGpPWpGaD
Amphetamine—SLC6A3—brain—conduct disorder	0.000348	0.0473	CbGeAlD
Amphetamine—SLC18A2—Neuronal System—COMT—conduct disorder	0.000347	0.00256	CbGpPWpGaD
Amphetamine—TAAR1—GPCR downstream signaling—DRD4—conduct disorder	0.000347	0.00255	CbGpPWpGaD
Amphetamine—SLC18A2—Neuronal System—MAOA—conduct disorder	0.000345	0.00254	CbGpPWpGaD
Amphetamine—DRD2—Class A/1 (Rhodopsin-like receptors)—CGA—conduct disorder	0.000336	0.00247	CbGpPWpGaD
Amphetamine—SLC22A3—Transmembrane transport of small molecules—GABRA2—conduct disorder	0.000335	0.00247	CbGpPWpGaD
Amphetamine—SLC22A5—Transmembrane transport of small molecules—GABRA2—conduct disorder	0.000334	0.00246	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—CGA—conduct disorder	0.000332	0.00245	CbGpPWpGaD
Amphetamine—SLC22A3—brain—conduct disorder	0.000328	0.0446	CbGeAlD
Amphetamine—SLC6A4—brain—conduct disorder	0.000319	0.0434	CbGeAlD
Amphetamine—TAAR1—Signaling by GPCR—DRD4—conduct disorder	0.000315	0.00232	CbGpPWpGaD
Amphetamine—MAOB—brain—conduct disorder	0.000303	0.0412	CbGeAlD
Amphetamine—DRD2—Circadian rythm related genes—SLC6A4—conduct disorder	0.000285	0.0021	CbGpPWpGaD
Amphetamine—SLC6A2—brain—conduct disorder	0.000281	0.0382	CbGeAlD
Amphetamine—SLC6A3—Transmission across Chemical Synapses—COMT—conduct disorder	0.00027	0.00199	CbGpPWpGaD
Amphetamine—SLC6A3—Transmission across Chemical Synapses—MAOA—conduct disorder	0.000268	0.00197	CbGpPWpGaD
Amphetamine—DRD2—Circadian rythm related genes—DRD4—conduct disorder	0.000268	0.00197	CbGpPWpGaD
Amphetamine—CYP2D6—Phase 1 - Functionalization of compounds—MAOA—conduct disorder	0.000267	0.00196	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—WASF1—conduct disorder	0.000266	0.00196	CbGpPWpGaD
Amphetamine—SLC6A2—Transmembrane transport of small molecules—GABRA2—conduct disorder	0.000261	0.00192	CbGpPWpGaD
Amphetamine—DRD2—brain—conduct disorder	0.000256	0.0348	CbGeAlD
Amphetamine—DRD2—GPCR ligand binding—CGA—conduct disorder	0.000256	0.00188	CbGpPWpGaD
Amphetamine—CYP2A6—Biological oxidations—COMT—conduct disorder	0.000255	0.00187	CbGpPWpGaD
Amphetamine—CYP2A6—Biological oxidations—MAOA—conduct disorder	0.000253	0.00186	CbGpPWpGaD
Amphetamine—SLC22A5—brain—conduct disorder	0.000238	0.0324	CbGeAlD
Amphetamine—DRD2—G alpha (i) signalling events—DRD4—conduct disorder	0.000237	0.00174	CbGpPWpGaD
Amphetamine—SLC6A3—Transmembrane transport of small molecules—GABRA2—conduct disorder	0.000231	0.0017	CbGpPWpGaD
Amphetamine—TAAR1—GPCR downstream signaling—HTR2A—conduct disorder	0.000226	0.00167	CbGpPWpGaD
Amphetamine—DRD2—GPCRs, Class A Rhodopsin-like—DRD4—conduct disorder	0.000219	0.00162	CbGpPWpGaD
Amphetamine—SLC6A3—Neuronal System—COMT—conduct disorder	0.000207	0.00152	CbGpPWpGaD
Amphetamine—TAAR1—Signaling by GPCR—HTR2A—conduct disorder	0.000206	0.00151	CbGpPWpGaD
Amphetamine—SLC6A3—Neuronal System—MAOA—conduct disorder	0.000205	0.00151	CbGpPWpGaD
Amphetamine—MAOB—Metabolism—CGA—conduct disorder	0.000198	0.00146	CbGpPWpGaD
Amphetamine—DRD2—Class A/1 (Rhodopsin-like receptors)—DRD4—conduct disorder	0.000188	0.00138	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—DRD4—conduct disorder	0.000186	0.00137	CbGpPWpGaD
Amphetamine—SLC6A4—SIDS Susceptibility Pathways—EP300—conduct disorder	0.000185	0.00137	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—CGA—conduct disorder	0.000167	0.00123	CbGpPWpGaD
Amphetamine—CYP2D6—brain—conduct disorder	0.000154	0.0209	CbGeAlD
Amphetamine—SLC6A4—Circadian rythm related genes—EP300—conduct disorder	0.000151	0.00111	CbGpPWpGaD
Amphetamine—DRD2—GPCR downstream signaling—CGA—conduct disorder	0.000145	0.00106	CbGpPWpGaD
Amphetamine—DRD2—GPCRs, Class A Rhodopsin-like—HTR2A—conduct disorder	0.000143	0.00105	CbGpPWpGaD
Amphetamine—DRD2—GPCR ligand binding—DRD4—conduct disorder	0.000143	0.00105	CbGpPWpGaD
Amphetamine—CYP2D6—Biological oxidations—COMT—conduct disorder	0.000143	0.00105	CbGpPWpGaD
Amphetamine—CYP2D6—Biological oxidations—MAOA—conduct disorder	0.000142	0.00104	CbGpPWpGaD
Amphetamine—CYP2D6—Metapathway biotransformation—COMT—conduct disorder	0.000141	0.00104	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—CGA—conduct disorder	0.000131	0.000966	CbGpPWpGaD
Amphetamine—DRD2—Class A/1 (Rhodopsin-like receptors)—HTR2A—conduct disorder	0.000123	0.000903	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—HTR2A—conduct disorder	0.000121	0.000894	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—CGA—conduct disorder	9.64e-05	0.00071	CbGpPWpGaD
Amphetamine—DRD2—GPCR ligand binding—HTR2A—conduct disorder	9.34e-05	0.000688	CbGpPWpGaD
Amphetamine—DRD2—Circadian rythm related genes—EP300—conduct disorder	9.26e-05	0.000682	CbGpPWpGaD
Amphetamine—MAOB—Metabolism—COMT—conduct disorder	8.94e-05	0.000658	CbGpPWpGaD
Amphetamine—MAOB—Metabolism—MAOA—conduct disorder	8.87e-05	0.000653	CbGpPWpGaD
Amphetamine—DRD2—GPCR downstream signaling—DRD4—conduct disorder	8.09e-05	0.000596	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—CGA—conduct disorder	7.75e-05	0.000571	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—COMT—conduct disorder	7.56e-05	0.000556	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—MAOA—conduct disorder	7.51e-05	0.000553	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—DRD4—conduct disorder	7.35e-05	0.000541	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—EP300—conduct disorder	6.43e-05	0.000474	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—WASF1—conduct disorder	6.21e-05	0.000457	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—CGA—conduct disorder	5.41e-05	0.000398	CbGpPWpGaD
Amphetamine—DRD2—GPCR downstream signaling—HTR2A—conduct disorder	5.28e-05	0.000389	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—HTR2A—conduct disorder	4.79e-05	0.000353	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—COMT—conduct disorder	4.35e-05	0.00032	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—DRD4—conduct disorder	4.34e-05	0.00032	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—MAOA—conduct disorder	4.32e-05	0.000318	CbGpPWpGaD
Amphetamine—MAOB—Metabolism—EP300—conduct disorder	3.83e-05	0.000282	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—EP300—conduct disorder	3.24e-05	0.000239	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—HTR2A—conduct disorder	2.83e-05	0.000208	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—COMT—conduct disorder	2.44e-05	0.00018	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—MAOA—conduct disorder	2.42e-05	0.000178	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—EP300—conduct disorder	1.87e-05	0.000137	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—EP300—conduct disorder	1.5e-05	0.00011	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—EP300—conduct disorder	1.05e-05	7.71e-05	CbGpPWpGaD
